Manager × security

MARK SHEPTOFF FINANCIAL PLANNING, LLC VRTX holdings history

Who else holds this security? →

VERTEX PHARMACEUTICALS INC · CUSIP 92532F100 · CIK 1607355

This is the oldest quarter open without an account, so changes against the quarter before it are withheld. Sign in to see them.
Citable facts

As of 2026-06-30, MARK SHEPTOFF FINANCIAL PLANNING, LLC reported 9.29K VRTX (shares), valued at $4.62M, or 2.45% of its reported non-derivative portfolio. Filed 2026-08-13.

Verify history & sources →
Portfolio weight and quantity history
Reported portfolio weight
2.45%
Shares
9.29K
9,295
Reported value
$4.62M
USD

Shares decreased 2.63%; reported value increased 13.98%, and weight changed +0.31 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.

Left: % · Right: Shares · Independently scaled axes

Exact data and methodology

Axes scale independently; a crossing does not mean equal values. Weight uses each quarter's total reported non-derivative value. Same CUSIP; missing quarters are gaps, not zero. Revised history may include later disclosures.

QuarterWeightQuantitySource
Q2 20262.45%9,295SEC filing ↗Filed Aug 13, 2026
Q1 20262.14%9,546SEC filing ↗Filed May 11, 2026
Q4 20252.21%10,246SEC filing ↗Filed Feb 12, 2026
Q3 20252.02%10,771SEC filing ↗Filed Nov 13, 2025
Q2 20252.56%10,771SEC filing ↗Filed Aug 6, 2025
Q1 20252.85%10,671SEC filing ↗Filed May 13, 2025
Q4 20242.39%11,071SEC filing ↗Filed Feb 12, 2025
Q3 20242.78%11,246SEC filing ↗Filed Nov 14, 2024
Q2 20242.99%11,422SEC filing ↗Filed Aug 12, 2024
Q1 20242.63%11,346SEC filing ↗Filed May 10, 2024
Q4 20232.77%11,296SEC filing ↗Filed Feb 9, 2024
Q3 20232.51%11,230SEC filing ↗Filed Nov 13, 2023

History & evidence by quarter

QuarterWeightQuantityValueChange explainedSource
Q3 20232.51%11,230$3.91MThe prior quarter is outside the free window. Sign in for the comparison.SEC filing ↗
Filed Nov 13, 2023
Q4 20232.77%11,296$4.60MShares increased 0.59%; reported value increased 17.70%, and weight changed +0.26 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 9, 2024
Q1 20242.63%11,346$4.74MShares increased 0.44%; reported value increased 3.19%, and weight changed -0.14 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 10, 2024
Q2 20242.99%11,422$5.35MShares increased 0.67%; reported value increased 12.88%, and weight changed +0.36 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 12, 2024
Q3 20242.78%11,246$5.23MShares decreased 1.54%; reported value decreased 2.31%, and weight changed -0.21 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 14, 2024
Q4 20242.39%11,071$4.46MShares decreased 1.56%; reported value decreased 14.76%, and weight changed -0.39 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 12, 2025
Q1 20252.85%10,671$5.17MShares decreased 3.61%; reported value increased 16.04%, and weight changed +0.46 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 13, 2025
Q2 20252.56%10,771$4.80MShares increased 0.94%; reported value decreased 7.31%, and weight changed -0.29 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 6, 2025
Q3 20252.02%10,771$4.22MShares unchanged; reported value decreased 12.03%, and weight changed -0.54 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Nov 13, 2025
Q4 20252.21%10,246$4.65MShares decreased 4.87%; reported value increased 10.12%, and weight changed +0.19 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Feb 12, 2026
Q1 20262.14%9,546$4.05MShares decreased 6.83%; reported value decreased 12.79%, and weight changed -0.07 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed May 11, 2026
Q2 20262.45%9,295$4.62MShares decreased 2.63%; reported value increased 13.98%, and weight changed +0.31 pp. Weight depends on both the security valuation and total portfolio value, not trade proceeds.SEC filing ↗
Filed Aug 13, 2026
MARK SHEPTOFF FINANCIAL PLANNING, LLC · VERTEX PHARMACEUTICALS INC

Take these holdings further.

This page includes 12 of 12 reported holdings. Sign in to look up the full history beyond 3 years, use advanced screening & filtering, download CSV, and get the complete set through the Akkru API.

  • Download CSV
  • Earlier quarters
  • Advanced screening & filtering
  • API & AI access
Already have an account?

+ New accounts get free API credits to explore data beyond ownership filings.

For AI agents & developers

The initial HTML of this page carries its exact data as script#research-data (JSON): values, units, scope, preview limits and SEC sources. Read it directly, no script or API key needed; script#research-access says what needs an account.

Without an account: the last 3 years, with the row caps stated on the page. A free account opens all history on file on these pages and the CSV of what a page shows. Rows beyond the caps and bulk retrieval go through the authenticated API / MCP.

MCP  https://api.akkrudata.ai/mcp

get_institutional_portfolio
{"cik":"1607355","quarter":"2026Q2","cusip":"92532F100"}

get_institutional_manager_history
{"cik":"1607355","page_size":100}

Connect to MCP with OAuth and follow the returned pagination. Credits and usage limits depend on the account.

MCP endpoint
https://api.akkrudata.ai/mcp
API / MCP documentation
/documents
llms.txt
/llms.txt
Sources, coverage & how to read this data

Figures are as reported to the SEC and merged with later amendments where Akkru could match them. Preview limits apply to what is listed, not to the totals, which come from the complete reported data. Nothing is zero-filled: a missing quarter or month is shown as missing.

13F reports quarter-end long positions in securities traded on US exchanges, filed by managers holding at least $100 million of such securities; it is not the manager's full portfolio, not assets under management, and value changes are not returns. Weights use the reported total value as denominator. Option rows show notional value, not premium or net exposure. Amendments are merged into the quarter when Akkru could match them.